Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Busillo, C.
Right arrow Articles by Talavera, W
Right arrow Search for Related Content
PubMed
Right arrow Articles by Busillo, C.
Right arrow Articles by Talavera, W

Chest, Vol 102, 797-801, Copyright © 1992 by American College of Chest Physicians

ARTICLES

Multidrug resistant Mycobacterium tuberculosis in patients with human immunodeficiency virus infection

CP Busillo, KD Lessnau, V Sanjana, S Soumakis, M Davidson, MP Mullen and W Talavera
Department of Medicine, Cabrini Medical Center, New York, New York 10003.

Multidrug resistant Mycobacterium tuberculosis (MDR-MTB) infection has not been recognized as a serious problem in patients with human immunodeficiency virus (HIV) infection. Multidrug resistance (MDR) has appeared in our medical center in 24 out of 72 patients between January 1990 and May 1991 compared to 8 out of 132 patients within the period from 1982 to 1987 (relative risk 5.50 with 95 percent confidence interval 2.61 to 11.61). We describe 19 patients with MDR in MTB (isoniazid and at least one additional first line drug), who had serologic evidence of HIV infection, 13 of whom were diagnosed with acquired immunodeficiency syndrome (AIDS). The MTB cultures from 10 out of 19 patients with MDR were resistant to three or more drugs. Fifteen patients died although 9 out of these 15 had received at least a four- drug regimen for a mean time of seven weeks (range 2 to 12). This increase in MDR was seen in ten homosexuals and nine intravenous drug users. This rapid appearance of MDR-MTB strains is worrisome. New strategies for empiric therapy of such patients while awaiting sensitivity data are needed.


This article has been cited by other articles:


Home page
 JAMAHome page
C. Dye, S. Scheele, P. Dolin, V. Pathania, M. C. Raviglione, and for the WHO Global Surveillance and Monitoring Pro
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
JAMA, August 18, 1999; 282(7): 677 - 686.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
T. V Perneger, P. Sudre, J. D Lundgren, and B. Hirschel
Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years
BMJ, December 2, 1995; 311(7018): 1468 - 1471.
[Abstract] [Full Text]

Home page
 NEJMHome page
M. D. Iseman
Treatment of Multidrug-Resistant Tuberculosis
N. Engl. J. Med., September 9, 1993; 329(11): 784 - 791.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American College of Chest Physicians.